Search Results

There are 2841 results for: content related to: Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

  1. Bezafibrate for primary biliary cirrhosis

    Intervention Review

    The Cochrane Library

    Jelena S Rudic, Goran Poropat, Miodrag N Krstic, Goran Bjelakovic and Christian Gluud

    Published Online : 18 JAN 2012, DOI: 10.1002/14651858.CD009145.pub2

  2. Effects of Bezafibrate—A Hypolipidemic Drug

    Cardiovascular Drug Reviews

    Volume 10, Issue 3, September 1992, Pages: 259–279, Dagny Ståhlberg

    Version of Record online : 2 APR 2007, DOI: 10.1111/j.1527-3466.1992.tb00250.x

  3. Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis

    Hepatology Research

    Volume 45, Issue 1, January 2015, Pages: 48–58, Yan Zhang, Kan Chen, Weiqi Dai, Yujing Xia, Fan Wang, Miao Shen, Ping Cheng, Chengfen Wang, Jing Yang, Rong Zhu, Huawei Zhang, Jingjing Li, Yuanyuan Zheng, Junshan Wang, Jie Lu, Yingqun Zhou and Chuanyong Guo

    Version of Record online : 28 JUL 2014, DOI: 10.1111/hepr.12373

  4. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis

    Journal of Hepato-Biliary-Pancreatic Sciences

    Volume 22, Issue 10, October 2015, Pages: 766–770, Suguru Mizuno, Kenji Hirano, Hiroyuki Isayama, Takeo Watanabe, Natsuyo Yamamoto, Yousuke Nakai, Naoki Sasahira, Minoru Tada, Masao Omata and Kazuhiko Koike

    Version of Record online : 21 AUG 2015, DOI: 10.1002/jhbp.281

  5. You have full text access to this Open Access content
    A metabolic shift induced by a PPAR panagonist markedly reduces the effects of pathogenic mitochondrial tRNA mutations

    Journal of Cellular and Molecular Medicine

    Volume 15, Issue 11, November 2011, Pages: 2317–2325, Tina Wenz, Xiao Wang, Matteo Marini and Carlos T. Moraes

    Version of Record online : 24 OCT 2011, DOI: 10.1111/j.1582-4934.2010.01223.x

  6. Effect of Bezafibrate on Monocyte Cytokine Release and Systemic Inflammation in Patients With Impaired Fasting Glucose

    The Journal of Clinical Pharmacology

    Volume 51, Issue 10, October 2011, Pages: 1459–1467, Robert Krysiak and Boguslaw Okopien

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270010382914

  7. You have free access to this content
    Turn up the power – pharmacological activation of mitochondrial biogenesis in mouse models

    British Journal of Pharmacology

    Volume 171, Issue 8, April 2014, Pages: 1818–1836, J C Komen and D R Thorburn

    Version of Record online : 28 MAR 2014, DOI: 10.1111/bph.12413

  8. Removal of naproxen and bezafibrate by activated sludge under aerobic conditions: Kinetics and effect of substrates

    Biotechnology and Applied Biochemistry

    Volume 61, Issue 3, May/June 2014, Pages: 333–341, Ying Tang, Xiao-Ming Li, Zhen-Cheng Xu, Qing-Wei Guo, Cheng-Yang Hong and Yong-Xin Bing

    Version of Record online : 24 MAR 2014, DOI: 10.1002/bab.1168

  9. Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-β1 in a cultured stellate cell line

    Hepatology Research

    Volume 38, Issue 10, October 2008, Pages: 1026–1039, Shigeru Nakano, Tatsuya Nagasawa, Tomoyuki Ijiro, Yoichi Inada, Toru Tamura, Kazuyasu Maruyama, Junji Kuroda, Yoshinobu Yamazaki, Hiroshi Kusama and Nobuo Shibata

    Version of Record online : 30 MAY 2008, DOI: 10.1111/j.1872-034X.2008.00363.x

  10. Double-blind Placebo-controlled Study of the Effects of Bezafibrate on Blood Lipids, Lipoproteins, and Fibrinogen in Hyperlipidaemic Type 1 Diabetes Mellitus

    Diabetic Medicine

    Volume 7, Issue 8, September/October 1990, Pages: 736–743, Dr P.H. Winocour, P.N. Durrington, D. Bhatnagar, M. Ishola, S. Arrol, B.C. Lalor and D.C. Anderson

    Version of Record online : 30 JUL 2009, DOI: 10.1111/j.1464-5491.1990.tb01479.x

  11. Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia

    European Journal of Clinical Investigation

    Volume 14, Issue 2, April 1984, Pages: 150–154, KLAUS VON BERGMANN and OTTMAR LEISS

    Version of Record online : 28 JUN 2008, DOI: 10.1111/j.1365-2362.1984.tb02105.x

  12. Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia

    Clinical Pharmacology & Therapeutics

    Volume 52, Issue 6, December 1992, Pages: 620–626, Pauli Karhapää, Matti Uusitupa, Erkki Voutilainen and Markku Laakso

    Version of Record online : 18 DEC 1992, DOI: 10.1038/clpt.1992.200

  13. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin

    Journal of Viral Hepatitis

    Volume 13, Issue 7, July 2006, Pages: 441–448, N. Fujita, M. Kaito, M. Kai, R. Sugimoto, H. Tanaka, S. Horiike, M. Konishi, M. Iwasa, S. Watanabe and Y. Adachi

    Version of Record online : 8 MAR 2006, DOI: 10.1111/j.1365-2893.2005.00718.x

  14. You have free access to this content
    Poster Session 1: Pathogenesis and Mechanisms; PBC/PSC and Other Cholestatic Disease

    Hepatology

    Volume 62, Issue S1, October 2015, Pages: 498A–530A,

    Version of Record online : 7 OCT 2015, DOI: 10.1002/hep.28214

  15. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid

    Liver International

    Volume 34, Issue 2, February 2014, Pages: 197–203, Sabela Lens, María Leoz, Leyla Nazal, Miguel Bruguera and Albert Parés

    Version of Record online : 2 SEP 2013, DOI: 10.1111/liv.12290

  16. Bezafibrate induced increase in mitochondrial electron transport chain complex IV activity in human astrocytoma cells: Implications for mitochondrial cytopathies and neurodegenerative diseases

    BioFactors

    Volume 36, Issue 6, November/December 2010, Pages: 468–473, Nicola Ioannou, Iain P. Hargreaves, George Allen, Kate Duberley, John M. Land and Simon J.R. Heales

    Version of Record online : 24 SEP 2010, DOI: 10.1002/biof.120

  17. You have free access to this content
    Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide

    British Journal of Clinical Pharmacology

    Volume 58, Issue 4, October 2004, Pages: 390–396, Lauri I. Kajosaari, Janne T. Backman, Mikko Neuvonen, Jouko Laitila and Pertti J. Neuvonen

    Version of Record online : 16 JUN 2004, DOI: 10.1111/j.1365-2125.2004.02158.x

  18. Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7α-hydroxylase

    Hepatology

    Volume 21, Issue 4, April 1995, Pages: 1025–1030, Dagny Ståhlberg, Eva Reihnér, Mats Rudling, Lars Berglund, Kurt Einarsson and Bo Angelin

    Version of Record online : 9 DEC 2005, DOI: 10.1002/hep.1840210421

  19. VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies

    BioFactors

    Volume 38, Issue 4, July/August 2012, Pages: 292–299, Mira Rosenblat, Sarah Ward, Nina Volkova, Tony Hayek and Michael Aviram

    Version of Record online : 4 JUN 2012, DOI: 10.1002/biof.1021

  20. Effects of Combined Bezafibrate-Simvastatin Appraised in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 32, Issue 5, May 1992, Pages: 422–426, Y. Horsmans, J. P. Desager and C. Harvengt

    Version of Record online : 8 MAR 2013, DOI: 10.1002/j.1552-4604.1992.tb03857.x